A head-to-head trial comparing decades-old steroid, prednisone, and new steroid, vamorolone, finds both act on same pathways involved in controlling inflammation, but vamorolone doesn’t activate pathways involved in prednisone’s undesirable side effects, making it a candidate for long-term use.

See the source article by following the link below:
A head-to-head trial comparing decades-old steroid, prednisone, and new steroid, vamorolone, finds both act on same pathways involved in controlling inflammation, but vamorolone doesn’t activate pathways involved in prednisone’s undesirable side effects, making it a candidate for long-term use.